ELAB
PMGC Holdings Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.21
−0.38%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.0M | 590.1K | 2.5M | — | 766.3K |
| Cost of Revenue | 2.7M | 515.3K | 670.2K | 554.00 | 319.0K |
| Gross Profit | 294.0K | 74.8K | 1.8M | (554.00) | 447.3K |
| Operating Expenses | |||||
| R&D Expense | 390.2K | 147.0K | 104.7K | 7.4K | 228.7K |
| SG&A Expense | 1.1M | 1.6M | 855.8K | 1.1M | 1.7M |
| General & Admin Expense | 945.1K | 1.4M | 563.2K | — | 1.5M |
| Selling & Marketing Expense | 112.7K | 200.9K | 292.5K | — | 192.9K |
| Other Expenses | 12.3M | 5.7M | 2.7M | — | 277.5K |
| Total Operating Expenses | 13.7M | 7.5M | 3.7M | 1.1M | 2.2M |
| Cost and Expenses | 16.4M | 8.0M | 4.3M | 1.1M | 2.6M |
| Operating Income (EBIT) | (13.4M) | (7.4M) | (1.9M) | (1.1M) | (1.8M) |
| Non-Operating | |||||
| Interest Income | 237.2K | 118.0K | 12.9K | 5.6K | 7.7K |
| Interest Expense | 3.1M | 547.1K | 735.2K | — | 2.6K |
| Net Interest Income | (2.8M) | (429.1K) | (722.3K) | 5.6K | 5.1K |
| Other Non-Op Income/Expense | (2.5M) | (373.1K) | (2.1M) | (515.8K) | (12.0K) |
| Non-Operating Income (excl Interest) | — | — | 1.4M | — | 9.3K |
| EBT (Pre-Tax Income) | (15.9M) | (7.7M) | (4.0M) | (1.7M) | (1.8M) |
| Income Tax Expense | 31.0K | 31.0K | — | — | — |
| Bottom Line | |||||
| Net Income | (15.9M) | (7.7M) | (6.2M) | (4.3M) | (1.8M) |
| Earnings from Cont. Ops | (15.9M) | (7.8M) | (4.0M) | (1.7M) | (1.8M) |
| Earnings from Discont. Ops | 78.3K | 72.6K | (2.2M) | (2.6M) | — |
| Bottom Line Net Income | (15.9M) | (7.7M) | (6.2M) | (4.3M) | (1.8M) |
| Per Share | |||||
| Basic EPS | ($648.07) | ($3,787.40) | ($65,923.20) | ($477,946.33) | ($158.40) |
| Diluted EPS | ($648.07) | ($3,787.40) | ($65,923.20) | ($1,511.43) | ($158.40) |
| Revenue Per Share | $6.10 | $289.97 | $25,971.56 | $0.00 | $67.55 |
| Shares | |||||
| Basic Shares Outstanding | 487650 | 2035 | 95 | 9 | 11344 |
| Diluted Shares Outstanding | 487650 | 2035 | 95 | 2846 | 11344 |
| Profitability Metrics | |||||
| EBITDA | (12.7M) | (7.3M) | (3.2M) | (1.1M) | (1.8M) |
| D&A | 684.0K | 110.5K | 83.1K | 554.00 | 6.5K |
| EBIT | (13.4M) | (7.4M) | (3.3M) | (1.1M) | (1.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026